Skip to main content
main-content

Zeitschrift

Investigational New Drugs

Investigational New Drugs 2/2018

Ausgabe 2/2018

Inhaltsverzeichnis ( 20 Artikel )

06.10.2017 | PRECLINICAL STUDIES | Ausgabe 2/2018

Hersintuzumab: A novel humanized anti-HER2 monoclonal antibody induces potent tumor growth inhibition

Mohammad Mehdi Amiri, Forough Golsaz-Shirazi, Tahereh Soltantoyeh, Reza Hosseini-Ghatar, Tannaz Bahadori, Jalal Khoshnoodi, Shadi Sadat Navabi, Samira Farid, Mohammad Hossein Karimi-Jafari, Mahmood Jeddi-Tehrani, Fazel Shokri

30.10.2017 | PRECLINICAL STUDIES | Ausgabe 2/2018

Systematic analysis reveals a lncRNA-mRNA co-expression network associated with platinum resistance in high-grade serous ovarian cancer

Lei Fang, Hao Wang, Peiling Li

07.11.2017 | PRECLINICAL STUDIES | Ausgabe 2/2018

Combination treatment with docetaxel and histone deacetylase inhibitors downregulates androgen receptor signaling in castration-resistant prostate cancer

Sang Eun Park, Ha-Gyeong Kim, Dong Eun Kim, Yoo Jung Jung, Yunlim Kim, Seong-Yun Jeong, Eun Kyung Choi, Jung Jin Hwang, Choung-Soo Kim

27.11.2017 | PRECLINICAL STUDIES | Ausgabe 2/2018

Antitumor activity of raloxifene-targeted poly(styrene maleic acid)-poly (amide-ether-ester-imide) co-polymeric nanomicelles loaded with docetaxel in breast cancer-bearing mice

Saeede Enteshari, Jaleh Varshosaz, Mohsen Minayian, Farshid Hassanzadeh

08.11.2017 | PRECLINICAL STUDIES | Ausgabe 2/2018

4EGI-1 represses cap-dependent translation and regulates genome-wide translation in malignant pleural mesothelioma

Arpita De, Blake A. Jacobson, Mark S. Peterson, Joe Jay-Dixon, Marian G. Kratzke, Ahad A. Sadiq, Manish R. Patel, Robert A. Kratzke

12.08.2017 | PHASE I STUDIES | Ausgabe 2/2018

First-in-human study of the epichaperome inhibitor PU-H71: clinical results and metabolic profile

Giovanna Speranza, Larry Anderson, Alice P. Chen, Khanh Do, Michelle Eugeni, Marcie Weil, Larry Rubinstein, Eva Majerova, Jerry Collins, Yvonne Horneffer, Lamin Juwara, Jennifer Zlott, Rachel Bishop, Barbara A. Conley, Howard Streicher, Joseph Tomaszewski, James H. Doroshow, Shivaani Kummar

18.08.2017 | PHASE I STUDIES | Ausgabe 2/2018 Open Access

Effect of alisertib, an investigational aurora a kinase inhibitor on the QTc interval in patients with advanced malignancies

Xiaofei Zhou, John Nemunaitis, Shubham Pant, Todd M. Bauer, Manish Patel, John Sarantopoulos, A. Craig Lockhart, Daniel Goodman, Dirk Huebner, Diane R. Mould, Karthik Venkatakrishnan

30.08.2017 | PHASE I STUDIES | Ausgabe 2/2018 Open Access

Effects of rifampin, itraconazole and esomeprazole on the pharmacokinetics of alisertib, an investigational aurora a kinase inhibitor in patients with advanced malignancies

Xiaofei Zhou, Shubham Pant, John Nemunaitis, A. Craig Lockhart, Gerald Falchook, Todd M. Bauer, Manish Patel, John Sarantopoulos, Michael Bargfrede, Andreas Muehler, Lakshmi Rangachari, Bin Zhang, Karthik Venkatakrishnan

07.09.2017 | PHASE I STUDIES | Ausgabe 2/2018

Safety, tolerability, and pharmacokinetic profile of dabrafenib in Japanese patients with BRAF V600 mutation-positive solid tumors: a phase 1 study

Yutaka Fujiwara, Naoya Yamazaki, Yoshio Kiyohara, Shusuke Yoshikawa, Noboru Yamamoto, Arata Tsutsumida, Hiroshi Nokihara, Kenjiro Namikawa, Akihira Mukaiyama, Fanghong Zhang, Tomohide Tamura

04.09.2017 | PHASE I STUDIES | Ausgabe 2/2018

Phase I dose escalation and pharmacokinetic study on the nanoparticle formulation of polymeric micellar paclitaxel for injection in patients with advanced solid malignancies

Meiqi Shi, Jing Sun, Jinsong Zhou, Hao Yu, Shaorong Yu, Guohao Xia, Li Wang, Yue Teng, Gangyi Liu, Chen Yu, Jifeng Feng, Yaling Shen

18.12.2017 | PHASE II STUDIES | Ausgabe 2/2018

A randomized phase 2 study of a HSP27 targeting antisense, apatorsen with prednisone versus prednisone alone, in patients with metastatic castration resistant prostate cancer

Evan Y. Yu, Susan L. Ellard, Sebastien J. Hotte, Joel R. Gingerich, Anthony M. Joshua, Martin E. Gleave, Kim N. Chi

26.12.2017 | PHASE II STUDIES | Ausgabe 2/2018

A phase IIa study of HA-irinotecan, formulation of hyaluronic acid and irinotecan targeting CD44 in extensive-stage small cell lung cancer

Muhammad Alamgeer, D. Neil Watkins, Ilia Banakh, Beena Kumar, Daniel J. Gough, Ben Markman, Vinod Ganju

27.01.2018 | PHASE II STUDIES | Ausgabe 2/2018

A phase II study of tipifarnib and gemcitabine in metastatic breast cancer

Clinton Yam, Rashmi K. Murthy, Vicente Valero, Janio Szklaruk, Girish S. Shroff, Carol J. Stalzer, Aman U. Buzdar, James L. Murray, Wei Yang, Gabriel N. Hortobagyi, Stacy L. Moulder, Banu Arun

02.05.2017 | PHASE III STUDIES | Ausgabe 2/2018

The outcome of sorafenib monotherapy on hepatocellular carcinoma with portal vein tumor thrombosis

Yuan-Hung Kuo, I-Pei Wu, Jing-Houng Wang, Chao-Hung Hung, Kun-Ming Rau, Chien-Hung Chen, Kwong-Ming Kee, Tsung-Hui Hu, Sheng-Nan Lu

14.11.2017 | PHASE III STUDIES | Ausgabe 2/2018

Phase III study of dulanermin (recombinant human tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand) combined with vinorelbine and cisplatin in patients with advanced non-small-cell lung cancer

Xuenong Ouyang, Meiqi Shi, Fangwei Jie, Yuxian Bai, Peng Shen, Zhuang Yu, Xiuwen Wang, Cheng Huang, Min Tao, Zhehai Wang, Conghua Xie, Qi Wu, Yongqian Shu, Baohui Han, Fengchun Zhang, Yiping Zhang, Chunhong Hu, Xitao Ma, Yongjie Liang, Anlan Wang, Bing Lu, Yi Shi, Jinfei Chen, Zhixiang Zhuang, Jiejun Wang, Jianjin Huang, Changhui Wang, Chunxue Bai, Xin Zhou, Qiang Li, Feng Chen, Hao Yu, Jifeng Feng

29.08.2017 | SHORT REPORT | Ausgabe 2/2018

Vinblastine and antihelmintic mebendazole potentiate temozolomide in resistant gliomas

Franciele Cristina Kipper, Andrew Oliveira Silva, André Luis Marc, Gláucia Confortin, Augusto Valadão Junqueira, Eliseu Paglioli Neto, Guido Lenz

11.09.2017 | SHORT REPORT | Ausgabe 2/2018

Characteristics of patients with sorafenib-treated advanced hepatocellular carcinoma eligible for second-line treatment

Sadahisa Ogasawara, Tetsuhiro Chiba, Yoshihiko Ooka, Eiichiro Suzuki, Takahiro Maeda, Masayuki Yokoyama, Toru Wakamatsu, Masanori Inoue, Tomoko Saito, Kazufumi Kobayashi, Soichiro Kiyono, Masato Nakamura, Shingo Nakamoto, Shin Yasui, Akinobu Tawada, Makoto Arai, Tatsuo Kanda, Hitoshi Maruyama, Osamu Yokosuka, Naoya Kato

30.09.2017 | SHORT REPORT | Ausgabe 2/2018

Association of Glutathione S-Transferase P-1 (GSTP-1) rs1695 polymorphism with overall survival in glioblastoma patients treated with combined radio-chemotherapy

Francesco Pasqualetti, Alessandra Gonnelli, Martina Cantarella, Durim Delishaj, Alessandro Molinari, Valerio Ortenzi, Francesco Carbone, Sabrina Montrone, Stefano Ursino, Sara Franceschi, Riccardo Morganti, Paola Orlandi, Teresa Di Desidero, Chiara Maria Mazzanti, Katia Zavaglia, Antonio Giuseppe Naccarato, Guido Bocci, Fabiola Paiar

25.10.2017 | SHORT REPORT | Ausgabe 2/2018 Open Access

Posterior reversible encephalopathy syndrome (PRES) induced by pazopanib, a multi-targeting tyrosine kinase inhibitor, in a patient with soft-tissue sarcoma: case report and review of the literature

Shoichi Deguchi, Koichi Mitsuya, Yoko Nakasu, Nakamasa Hayashi, Hirohisa Katagiri, Hideki Murata, Junji Wasa, Mitsuru Takahashi, Masahiro Endo

11.10.2017 | SHORT REPORT | Ausgabe 2/2018

Gastrointestinal perforation related to lenvatinib, an anti-angiogenic inhibitor that targets multiple receptor tyrosine kinases, in a patient with metastatic thyroid cancer

Emi Date, Kunio Okamoto, Souichi Fumita, Hiroyasu Kaneda

Aktuelle Ausgaben


 

Neu im Fachgebiet Onkologie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Onkologie und bleiben Sie gut informiert – ganz bequem per eMail.

Bildnachweise